MREO

1.76

2.92% 0.05

Vorhandelsmarkt: 1.76

Mereo Biopharma Group Plc Adr (MREO)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose

Schlusskurs vom Vortag:

$1.71

Offen:

$1.7

24-Stunden-Volumen:

1.84M

Relative Volume:

0.84

Marktkapitalisierung:

$279.84M

Einnahmen:

$10.00M

Nettoeinkommen (Verlust:

$-29.47M

KGV:

-8.80

EPS:

-0.2

Netto-Cashflow:

$-21.55M

1W Leistung:

+2.92%

1M Leistung:

-38.25%

6M Leistung:

-39.73%

1J Leistung:

-55.78%

1-Tages-Spanne:

$1.70

$1.775

1-Wochen-Bereich:

$1.65

$1.87

52-Wochen-Spanne:

$1.57

$5.02

Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile

Firmenname

Mereo Biopharma Group Plc Adr

Sektor

Healthcare (1161)

Branche

Biotechnology (653)

Telefon

4403330237300

Adresse

ONE CAVENDISH PLACE, LONDON

Mitarbeiter

Twitter

@MereoBioPharma

Nächster Verdiensttermin

2025-03-26

Neueste SEC-Einreichungen

MREO's Discussions on Twitter

Vergleichen Sie MREO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MREO Mereo Biopharma Group Plc Adr	1.76	271.89M	10.00M	-29.47M	-21.55M	-0.20
VRTX Vertex Pharmaceuticals Inc	470.13	119.21B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	560.93	59.16B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	325.28	40.57B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	571.23	34.02B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	295.59	29.19B	3.81B	-644.79M	-669.77M	-6.24

Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-03-27	Eingeleitet	JP Morgan	Overweight
2024-12-06	Eingeleitet	Jefferies	Buy
2024-06-13	Eingeleitet	Robert W. Baird	Outperform
2023-10-13	Fortgesetzt	BTIG Research	Buy
2022-08-12	Eingeleitet	Cantor Fitzgerald	Overweight
2021-05-05	Eingeleitet	BTIG Research	Buy
2021-04-05	Eingeleitet	Needham	Buy

Alle ansehen

Mereo Biopharma Group Plc Adr Aktie (MREO) Neueste Nachrichten

Jul 22, 2025

MREO ACTIVE INVESTIGATION: Lost Money on Mereo BioPharma Group plc? Contact Levi & Korsinsky Now - ACCESS Newswire

Jul 22, 2025

Mereo BioPharma Group plc (MREO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jul 22, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plcMREO - PR Newswire

Jul 22, 2025

Jul 21, 2025

Mereo BioPharma Group plc (MREO) Under Investigation for Potential Securities Law ViolationsContact Levi & Korsinsky Today - ACCESS Newswire

Jul 21, 2025

Investigation Opened on Behalf of Mereo BioPharma Group plc (MREO) ShareholdersContact Levi & Korsinsky - ACCESS Newswire

Jul 21, 2025

Jul 20, 2025

Ongoing Securities Investigation into Mereo BioPharma Group plc (MREO)Contact Levi & Korsinsky - ACCESS Newswire

Jul 20, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Mereo BioPharma Group plc (MREO) And Encourages Stockholders to Connect - ACCESS Newswire

Jul 20, 2025

Jul 19, 2025

Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Given Consensus Rating of “Buy” by Brokerages - Defense World

Jul 19, 2025

Investigation Underway: Mereo BioPharma Group plc (MREO)Contact Levi & Korsinsky Over Securities Law Violations - ACCESS Newswire

Jul 19, 2025

Jul 18, 2025

Mereo BioPharma Group plc (MREO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jul 18, 2025

MREO ALERT: Ongoing Investigation Into Mereo BioPharma Group plcContact Levi & Korsinsky - ACCESS Newswire

Jul 18, 2025

Jul 17, 2025

Protect Your Investment: Contact Levi & Korsinsky About the Mereo BioPharma Group plc (MREO) Investigation - ACCESS Newswire

Jul 17, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mereo BioPharma Group plc (MREO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Jul 17, 2025

Jul 11, 2025

BTIG reiterates Buy rating on Mereo BioPharma stock amid trial progress By Investing.com - Investing.com South Africa

Jul 11, 2025

Jul 10, 2025

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.43% - Investing.com

Jul 10, 2025

United States shares higher at close of trade; Dow Jones Industrial Average up 0.43% - Investing.com India

Jul 10, 2025

RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End - Yahoo Finance

Jul 10, 2025

JPMorgan maintains Mereo BioPharma stock rating despite trial setback By Investing.com - Investing.com India

Jul 10, 2025

JPMorgan maintains Mereo BioPharma stock rating despite trial setback - Investing.com

Jul 10, 2025

Mereo BioPharma and Ultragenyx advance Phase 3 Orbit study for osteogenesis imperfecta - Investing.com India

Jul 10, 2025

Jun 09, 2025

SEC Form N-CSRS filed by abrdn World Healthcare Fund Shares of Beneficial Interest - Quantisnow

Jun 09, 2025

May 22, 2025

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), ACADIA Pharmaceuticals (ACAD) and Quanterix (QTRX) - The Globe and Mail

May 22, 2025

May 21, 2025

Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Stock Sentiment: What’s Wall Street Saying? - Stocksregister

May 21, 2025

May 16, 2025

Analysts Offer Insights on Healthcare Companies: Organon (OGN), Diamedica Therapeutics (DMAC) and Nkarta (NKTX) - The Globe and Mail

May 16, 2025

May 13, 2025

Mereo BioPharma Group plc SEC 10-Q Report - TradingView

May 13, 2025

Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights - GlobeNewswire

May 13, 2025

May 01, 2025